Correlation Analysis Of Serum P110α And Gal-3 Expression With Cardiac Hypertrophy And Prognosis In Hypertensive Patients

The heart develops into compensatory cardiomyopathy due to various stresses and pathological conditions,leading to life-threatening diseases such as arrhythmia,heart failure,and sudden cardiac death [1].Short-term reconfiguration of the heart to maintain blood in various tissue organs is beneficial,and prolonged reconfiguration leads to heart failure.The prevalence of LVH varies greatly depending on age and comorbidities,and the prevalence of LVH in hypertensive patients in Japan reaches 42.7%[2].According to new data,the number of hypertension patients in China has reached245 million [3],and the number of patients with cardiomyopathy is overwhelmingly high.Many studies have shown that LVH significantly increases the risk of cardiovascular disease.Therefore,exploring the pathogenesis of cardiovascular hypertrophy and finding applicable clinical preventative measures to ease the social and economic burden arising from cardiovascular disease is one of the challenges to be addressed in the cardiovascular field.ObjectiveTo investigate the relationship between the expression of p110α and Gal-3 in serum and cardiac hypertrophy in patients with cardiac hypertrophy and the correlation analysis of prognosis.MethodsFrom August to December 2020,200 hypertension patients in the cardiology department of the hospital were selected as research subjects.The study was divided into 100 cases（hypertension with hypercardiomyopathy）and 100 control cases（hypertension without hypercardiomyopathy）.When we compare the expression levels of p110 alpha and factor gal-3 in serum.A total of 200 hypertensive patients admitted to the Department of Cardiology,Single-factor analysis and multi-factor logistic regression analysis in hypertensive patients with myocardial hypertrophy,causal factors associated with adverse events of cardiovascular and cerebrovascular occur.ResultsWe compared the levels of gal-3 factor p110 alpha in the serum of the two groups.The case groups（5.16±0.27,11.77±1.08）were significantly higher than the control groups（4.01±0.69,8.34±0.94）.Statistically significant difference（p<0.05）.Diabetes（or =1.432）,hyperlipidemia（or =2.500）,p110 alpha（or =4.947）,and gal-3（or =1.700）were all correlated factors for adverse events of the cardiovascular system in hypertensive patients（p<0.05）.ConclusionThe expression levels of p110 alpha and factor gal-3 in serum in the case group（hypertensive cardiomyopathy group）were significantly higher than in the controlgroup（non-cardiomyopathy group）,People with hypertension,myocardial hypertrophy,abnormal blood sugar and abnormal blood fat are at a significantly higher risk of cardiovascular failure;In addition,the risk of adverse events in the cardiovascular system in people with hypertensive cardiomyopathy is significantly correlated with the expression levels of p110 alpha and factor gal-3 in the serum.According to the research results blood glucose abnormalities dyslipidemia are harmful cardiovascular event an independent risk factors,hypertension muscle thickens group,according to the research results blood glucose abnormalities dyslipidemia are harmful cardiovascular event an independent risk factors,hypertension muscle thickens group,The risk of cardiovascular adverse events in people with diabetes mellitus is1.432 times greater than in people without diabetes mellitus（or =1.432）;Hypertensive myocardial hypertrophy is associated with hyperlipidemia,and the risk of heart and cerebrovascular failure is 2.5 times higher than that of people without hyperlipidemia（or= 2.500）;Positive correlation between high serum expression levels of p110 alpha and factor gal-3 and risk of cardiovascular adverse events（p<0.05）,For every unit increase in serum p110 alpha factor levels,the risk of cardiovascular disease was increased 4.947 times（or =4.947）,For every unit increase in the concentration of gal-3factor in serum,the risk of cardiovascular injury was increased by 1.7 times（or=1.700）.Therefore,the risk of adverse events in the cardiovascular system can be evaluated according to the expression level of p110 alpha and factor gal-3 in the serum of patients with myocardial hypertrophy.To give them the right treatment,You can reduce the incidence of cerebrovascular disease.